99% Purity CAS 915087-33-1 Enzalutamide Powder Chemical Enzalutamide Powder Enzalutamide

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Enzalutamide
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Molecular Weight: 464.43600
• Psa: 108.53000
• Refractive Index: 1.629
• Density: 1.49
• Molecular Formula: C21h16f4n4o2s
• CAS No.: 915087-33-1
• Shelf Life: 2 Years
• Test Method: HPLC
• Specific: COA
• Application: Anticancer
• Assay: HPLC 99%
• Grade: Pharmaceutical Grade
• Color: White
• Name: Enzalutamide Powder
• Product Name: Enzalutamide
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• HS Code: 2933990090
• Production Capacity: 50kg/Month

Product Description

 

Product Description

99% purity CAS 915087-33-1 Enzalutamide powder Chemical Enzalutamide powder Enzalutamide

Product Description

Product Details

Product Name	Enzalutamide
CAS NO.	915087-33-1
Purity	99%
Density	1.49
Appearance and shape	White powder

Enzalutamide is an androgen receptor inhibitor, it can competitively inhibit androgen and receptor binding, and can inhibition of androgen receptor nuclear transport and the interaction of the receptor and DNA. Vitro studies have shown that enzalutamide can inhibit prostate cancer cell proliferation and induce death, and enzalutamide reduces tumor volume in mouse prostate cancer xenograft model experiment. The main metabolite of enzalutamide is N-demethylol enamine, which shows similar inhibitory activity with enzalutamide in vitro. The recommended adult dose for the drug is daily 160mg, rapidly absorbed after medication, plasma concentrations to reach the highest level in 0.5~3h, the average terminal half-life is 5.8d, the main metabolic enzymes are CYP2C8 and CYP3A4.

Application & Function

Function
1.Enzalutamide is clinically effective in the treatment of mCRPC.
2.Treatment of metastatic castration resistant prostate cancer.
3.Enzalutamide can be used as an antiandrogen in feminizing hormone therapy for transgender women.
Application
Enzalutamide (XTANDI, enzalutamide) is an oral androgen receptor antagonist. It is currently clinically studied and approved by the US FDA (Food and Drug Administration) Chemicalbook for use in metastatic castration-resistant prostate cancer that has progressed after chemotherapy. The treatment of prostate cancer (that is, patients with prostate cancer whose tumor or cancer cells are still growing after chemotherapy) can prolong the survival time of the patient.

Specification